Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
University of British Columbia · AIDS Vancouver · +20 more institutions
Abstract
Combination antiretroviral therapy (ART) has significantly increased survival among HIV-positive adults in the United States (U.S.) and Canada, but gains in life expectancy for this region have not been well characterized. We aim to estimate temporal changes in life expectancy among HIV-positive adults on ART from 2000-2007 in the U.S. and Canada.
Participants were from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), aged ≥20 years and on ART. Mortality rates were calculated using participants' person-time from January 1, 2000 or ART initiation until death, loss to follow-up, or administrative censoring December 31, 2007. Life expectancy at age 20, defined as the average number of additional years that a person of a specific age will live, provided the current age-specific mortality rates remain constant, was estimated using abridged life tables.
Citation impact
- FWCI
- 57.43
- Percentile
- 100%
- References
- 33
Authors
26- HSHasina Samji
University of British Columbia, AIDS Vancouver
- ACAngela Cescon
University of British Columbia, AIDS Vancouver
- RSRobert S. HoggCorresponding
University of British Columbia, Simon Fraser University, AIDS Vancouver
- SPSharada P. Modur
Johns Hopkins University
- KNKeri N. Althoff
Johns Hopkins University
Topics & keywords
- Life expectancy
- Demography
- Cohort
- Gerontology
- Medicine
- Mortality rate
- Censoring (clinical trials)
- Human immunodeficiency virus (HIV)
- Good health and well-being
Funding
- NINational Institutes of HealthAwards: AI35039, K24-DA00432, CBR-86906, U01-AI34993, K23-EY013707, K24 AI65298, CBR-94036, CDC200-2006-18797, U01-AI35039, AI65298, U01-AI35004, U10-AA13566, HCP-97105, U01-AI31834, U01-AI34994, TGF-96118, U01-AI34989, K01-AI093197, U01-AI069918
- CFCenters for Disease Control and PreventionAwards: K23-EY013707, U01-AI35039, CDC200-2006-18797, HCP-97105, CBR-94036, TGF-96118, U01-AI34994, CBR-86906, U01-AI31834, K01-AI093197, U01-AI069918, U01-AI34989, U01-AI35004, K24-DA00432
- AFAgency for Healthcare Research and QualityAwards: U01-AI35039, U01-AI069918, TGF-96118, U01-AI35004, HCP-97105, CBR-94036, K01-AI093197, K23-EY013707, U01-AI34994, 290-01-0012, CDC200-2006-18797, U01-AI34993, CBR-86906, U01-AI31834, U01-AI34989, K24-DA00432
- CICanadian Institutes of Health ResearchAwards: U01-AI069918, CDC200-2006-18797, TGF-96118, K01-AI093197, K23-EY013707, HCP-97105, U01-AI34989, K24-DA00432, U01-AI34994, U01-AI34993, U01-AI31834, CBR-86906, CBR-94036, U01-AI35004, U01-AI35039